Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease

NACompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

January 31, 2018

Conditions
Ischemic Heart DiseaseBone Marrow CellsCoronary Artery Bypass Grafting (CABG)Heart Failure, Diastolic
Interventions
PROCEDURE

Group 1

Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.

PROCEDURE

Group 0

Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.

PROCEDURE

Group 2

Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.

Trial Locations (1)

197089

First Pavlov State Medical University of St. Petersburg, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER

NCT02059512 - Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease | Biotech Hunter | Biotech Hunter